Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Biosimilars

Research Grade Obiltoxaximab (JN898016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.JN898016
Species reactivityBacillus anthracis
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host speciesChimeric
IsotypeIgG1-kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession P13423
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate NamesETI-204, 1351337-07-9
BackgroundObiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax.
Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • SEC-HPLC

    SEC-HPLC detection for Research Grade Obiltoxaximab.

  • Bioactivity

    Detects PA/pagA/PA-83 in indirect ELISAs.

  • SDS-PAGE

    SDS-PAGE for Research Grade Obiltoxaximab

  • Western blot

    Western blot analysis was performed using anti-PA/pagA/PA-83 monoclonal antibody at 1μg/ml on various samples.
    Lane 1: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 50ng
    Lane 2: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 30ng
    Lane 3: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 20ng
    Lane 4: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 10ng

References
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list